Fannin Innovation Studio

Chairman and Founder Leo Linbeck III sets the strategic direction; day-to-day investment and product development decisions are driven by Managing Partner Atul Varadhachary, M.D., Ph.D., and Managing Director Dev Chatterjee, M.D., M.S., Ph.D. The core team includes a dedicated clinical development operations manager, scientists, and product development associates who collectively advance the pipeline.

Fannin sources exclusively through academic partnerships, collaborating with researchers at major institutions such as MD Anderson Cancer Center, Baylor College of Medicine, Texas Heart Institute, and Imperial College London. The firm embeds a product development team alongside academic inventors rather than licensing assets externally. This proprietary, relationship-driven model provides continuous access to innovations emerging from Houston’s largest research hospitals.

Fannin operates as an early-stage product development studio, not a single family office. It functions as a hybrid: it provides management services and internal scientific talent to portfolio programs while also serving as the early investor, blending grant funding with investor capital. The firm does not raise traditional blind-pool venture funds; instead it invests directly into Fannin-founded entities.

Fannin focuses solely on direct investments into programs and entities it founds or co-develops, rather than committing capital to third-party venture funds. Its $260 million deployment figure represents capital invested across more than 35 programs, with approximately $185 million from investors and $75 million from grant funding (per firm website).

Fannin targets the earliest stages of product development — seed and startup phases, frequently beginning at the point of academic invention. The firm advances pharmaceutical and medical device programs through preclinical and clinical development, with three programs currently in clinical trials. Its model is designed to bridge the gap between university research and traditional Series A venture investment.

Fannin serves as the founding management team and initial investor for its portfolio entities. For example, Allterum Therapeutics was formed in February 2020 to advance a therapeutic antibody from MD Anderson’s Scott K. Durum lab, with Fannin providing operational leadership and early capital. Procyrion and Pulmotect have their own CEOs and presidents but maintain shared R&D infrastructure and governance ties back to the studio.

Fannin does not publicly disclose its limited partner base or wealth origin. The firm’s deployable capital includes both investor commitments and non-dilutive grant funding from federal and institutional sources. Publicly confirmed partners are academic collaborators, not named financial sponsors.